Meta Information
ID:bisphosphonates
Name:Bisphosphonates
Schema Version:1.5
Alternate Names
- BPs
Intervention Type
therapeutic_agent
Expected Cost Mean
Low Cost:
10
High Cost:
150
Cost Type:
monthly
Description:
Generic oral versions are inexpensive; IV infusions are pricier but often insurance-covered.
Summary
Bisphosphonates are a class of drugs that slow bone loss by inhibiting osteoclasts, the cells responsible for bone resorption. Their primary healthspan relevance is the prevention of osteoporosis and associated fractures, which are a major cause of morbidity, loss of independence, and mortality in older adults. Some observational data suggests a potential reduction in all-cause mortality, though the mechanism is not fully understood.
Purpose
Inhibits bone breakdown to prevent age-related osteoporosis and fractures.
Card Summary
A class of drugs that prevent bone loss by inhibiting osteoclasts, primarily used to treat and prevent osteoporosis, a major age-related disease.
Drug Class
Drugs In Class
- alendronate
- risedronate
- ibandronate
- zoledronic_acid
- pamidronate
Impact
Score:
7.2
Justification:
Dramatically reduces fracture risk, a major cause of age-related morbidity and mortality.
Evidence
Grade:
A
Score:
9.5
Justification:
Extensive, large-scale human RCTs and meta-analyses confirm efficacy for fracture prevention.
Safety
Score:
5.5
Justification:
Prescription drug with rare but serious risks like ONJ and atypical fractures.
Flags
- Requires a prescription and medical supervision.
- Oral forms can cause significant gastrointestinal and esophageal irritation.
- Long-term use is associated with rare risks of osteonecrosis of the jaw (ONJ) and atypical femur fractures.
- Proper administration of oral pills (e.g., with water, remaining upright) is critical to minimize side effects.
- Contraindicated in patients with severe kidney impairment.
- Absorption is significantly reduced by food, calcium, and antacids.
Verdict
Highly effective for bone health, a crucial component of healthspan.
Created
2026-04-26T18:29:50.147601Z
Model
Gemini 3.1 Pro (High)
Delivery
Route:
oral
Scope:
- systemic
Indication
Focus:
healthspan
Description:
Bisphosphonates are a class of drugs that slow bone loss by inhibiting osteoclasts, the cells responsible for bone resorption. Their primary healthspan relevance is the prevention of osteoporosis and ...
Typical Protocol
- Oral forms are typically taken daily, weekly, or monthly (e.g., alendronate 70mg once weekly).
- Intravenous forms are administered less frequently, such as quarterly or yearly (e.g., zoledronic acid 5mg once yearly).